BR112014029308A2 - um método de melhorar a função hepática - Google Patents

um método de melhorar a função hepática

Info

Publication number
BR112014029308A2
BR112014029308A2 BR112014029308A BR112014029308A BR112014029308A2 BR 112014029308 A2 BR112014029308 A2 BR 112014029308A2 BR 112014029308 A BR112014029308 A BR 112014029308A BR 112014029308 A BR112014029308 A BR 112014029308A BR 112014029308 A2 BR112014029308 A2 BR 112014029308A2
Authority
BR
Brazil
Prior art keywords
liver function
improving liver
improving
liver
metazolamide
Prior art date
Application number
BR112014029308A
Other languages
English (en)
Inventor
Nicholson Geoff
Krippner Guy
Walder Ken
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of BR112014029308A2 publication Critical patent/BR112014029308A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo “um método de melhorar a função hepática” a presente divulgação refere-se de modo geral ao uso de metazolamida em terapia. a divulgação tem ainda refere-se ao tratamento da disfunção do fígado, ou a melhoria da função do fígado, em um paciente.
BR112014029308A 2012-05-24 2013-03-15 um método de melhorar a função hepática BR112014029308A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261666574P 2012-06-29 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (1)

Publication Number Publication Date
BR112014029308A2 true BR112014029308A2 (pt) 2017-06-27

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029308A BR112014029308A2 (pt) 2012-05-24 2013-03-15 um método de melhorar a função hepática

Country Status (15)

Country Link
US (2) US20150150855A1 (pt)
EP (1) EP2854807A4 (pt)
JP (2) JP6360826B2 (pt)
KR (1) KR20150023405A (pt)
CN (2) CN104487073A (pt)
BR (1) BR112014029308A2 (pt)
CA (1) CA2874513A1 (pt)
CO (1) CO7160082A2 (pt)
HK (1) HK1209051A1 (pt)
MX (1) MX362111B (pt)
NZ (2) NZ723206A (pt)
RU (1) RU2653478C2 (pt)
SG (2) SG11201407787VA (pt)
WO (1) WO2013173859A1 (pt)
ZA (1) ZA201408704B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
JP6438389B2 (ja) * 2012-05-24 2018-12-12 ネイア メタボリック、インコーポレイテッド 減量法
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
SG130189A1 (en) 2003-08-01 2007-03-20 Janssen Pharmaceutica Nv Substituted indole-o-glucosides
PL2106260T3 (pl) * 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
JP6438389B2 (ja) * 2012-05-24 2018-12-12 ネイア メタボリック、インコーポレイテッド 減量法

Also Published As

Publication number Publication date
CO7160082A2 (es) 2015-01-15
RU2653478C2 (ru) 2018-05-08
JP6412241B2 (ja) 2018-10-24
JP2018090589A (ja) 2018-06-14
EP2854807A4 (en) 2016-03-16
MX2014014317A (es) 2015-08-10
HK1209051A1 (en) 2016-03-24
SG11201407787VA (en) 2014-12-30
RU2014152196A (ru) 2016-07-20
EP2854807A1 (en) 2015-04-08
NZ723206A (en) 2018-02-23
MX362111B (es) 2019-01-07
JP2015517534A (ja) 2015-06-22
KR20150023405A (ko) 2015-03-05
JP6360826B2 (ja) 2018-07-18
SG10201705388XA (en) 2017-07-28
WO2013173859A1 (en) 2013-11-28
NZ702645A (en) 2016-08-26
US20150150855A1 (en) 2015-06-04
CN104487073A (zh) 2015-04-01
CA2874513A1 (en) 2013-11-28
ZA201408704B (en) 2018-07-25
CN109498623A (zh) 2019-03-22
US20180333399A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2011328009A8 (en) Compounds and methods for treating pain
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX368346B (es) Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
MX2016008448A (es) Conjugados de var2csa-farmaco.
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PH12015501088A1 (en) Dimeric compounds
IN2014DN09228A (pt)
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MX364220B (es) Metodos de tratamientos de fibrosis.
NZ628433A (en) Chitosan-derived compositions
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]